REO 002

Local Monotherapy of REOLYSIN® for Patients with T2 Prostate Cancer

In February 2004, Oncolytics released the final results from its completed clinical trial examining the use of REOLYSIN^® in cancer confined to the prostate gland. Patients were treated with a single injection of REOLSYIN^® directly into the prostate gland and were monitored for approximately three weeks prior to the surgical removal of the prostate. Final results showed evidence of apoptotic tumor cell death in four of six patients, with no safety concerns. A fifth patient saw prostate-specific antigen (PSA) levels drop by 53% and prostate shrinkage of 67% during the three week period from just prior to treatment until surgical removal. The primary endpoints of this study were to examine the safety and the histopathological efficacy of intratumoral administration of REOLYSIN^® for the treatment of cancer that is restricted to the prostate gland.

Links:

• March 15, 2010: Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic (PDF)

• February 27, 2004: Oncolytics Biotech Provides Final Update on T2 Prostate Cancer Study (Press Release)

• March 31, 2003: Oncolytics Biotech Inc. Reports Presentation of Results From Interim Assessment of T2 Prostate Cancer Trial (Press Release)